Captrust Financial Advisors Outlook Therapeutics, Inc. Transaction History

Captrust Financial Advisors

  • $33 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$0.22 - $0.66 $13,200 - $39,600
-60,000 Reduced 44.07%
76,138 $29,000
Q3 2023

Nov 14, 2023
BUY
$0.2 - $1.78 $23,114 - $205,714
115,570 Added 561.89%
136,138 $29,000
Q2 2023

Aug 14, 2023
BUY
$1.02 - $1.89 $10,200 - $18,900
10,000 Added 94.63%
20,568 $35,000
Q1 2023

May 15, 2023
BUY
$1.0 - $1.35 $10,568 - $14,266
10,568 New
10,568 $11,000
Q1 2022

May 16, 2022
BUY
$1.22 - $2.03 $12,200 - $20,299
10,000 New
10,000 $18,000

Others Institutions Holding OTLK

# of Institutions
3
Shares Held
31.5K
Call Options Held
0
Put Options Held
0
View Full List

About Outlook Therapeutics, Inc.

OTLK Quotes by TradingView
  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $326M
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email